Skip to content
Review Open access

Differentiated strategies for antidepressant augmentation: focus on aripiprazole

Oct 2026 · Neurology, neuropsychiatry, Psychosomatics · 0 citations · 19 references

TL;DR

Aripiprazole is found to be particularly effective not only in anhedonia, apathy, reduced motivation, and cognitive impairment, but also in comorbid obsessive-compulsive and hyperkinetic disorders.

Abstract

Unipolar depression is highly prevalent in the population and has a significant impact on quality of life and somatic health. Despite the high efficacy of antidepressants, a substantial proportion of patients demonstrate an incomplete response to first-line therapy. One of the most evidence-based augmentation strategies is the addition of atypical antipsychotics. This review examines the pharmacological properties, efficacy, and tolerability of aripiprazole compared with quetiapine in unipolar depression. Partial agonism at D2 receptors and activity at serotonin receptors make aripiprazole particularly effective not only in anhedonia, apathy, reduced motivation, and cognitive impairment, but also in comorbid obsessive-compulsive and hyperkinetic disorders. Quetiapine, by contrast, may be preferable when anxiety and sleep disturbances predominate. When selecting a drug, it is essential to consider differences in adverse event profiles, including cardiometabolic effects, akathisia, weight gain, and the risk of restless legs syndrome. A differentiated choice of antipsychotic based on the clinical structure of depression allows optimization of the augmentation strategy and increases the likelihood of therapeutic response.

Read PDF

Similar papers

Review Open access Oct 2026

The Use of Cariprazine in the Treatment of Major Depression with Insufficient Response for Antidepressant: Effects on Symptomatic Domains

Background : antidepressants (ADs) are recognized as first-line drugs in the treatment of depressive disorder. However, therapeutic response is only achieved in 50–75% of cases, necessitating the search for additional treatment strategies, including augmentation of antidepressant therapy. In this connection the stud...

N. Lutova, D. V. Bobrik · 0 citations
Review Open access Sep 2026

EFFICACY AND SAFETY OF PSILOCYBIN IN TREATMENT-RESISTANT DEPRESSION: A REVIEW

Major depressive disorder (MDD) is one of the leading causes of disability worldwide. A substantial proportion of patients fail to achieve remission through standard monoaminergic therapies, meeting the clinical criteria for treatment-resistant depression (TRD). TRD is associated with significant clinical morbidity and...

Mateusz Gawin, Emilia Koziara, Mateusz Gadzina et al. · 0 citations
Case report Oct 2026

Cariprazine: Pharmacology, Indications, Dosing Guidelines and Adverse Effects

After completing this activity, participants should be able to: Differentiate cariprazine from aripiprazole and from higher-efficacy antipsychotics: identify the approval aripiprazole lacks (bipolar I depression, first-line in the 2023 CANMAT/ISBD update); place cariprazine in a 2026 network meta-analysis of 24 antipsy...

Sebastián Malleza · 0 citations
Review Open access Sep 2026

Treatment-Resistant Depression: A Literature Review of Innovative and Emerging Treatment Strategies

Introduction and objective: Major depressive disorder (MDD) is a heterogeneous psychiatric condition characterized by affective, cognitive and somatic symptoms that considerably impair daily functioning. It is defined clinically by prolonged low mood, diminished interest or pleasure, and a range of associated disturban...

Maciej Kisielewski, Natalia Fidut, Jakub Skrzypek et al. · 0 citations
Review Open access Sep 2026

A Review of the Efficacy and Adverse Effects of Fluoxetine in the Treatment of Generalized Anxiety Disorder

Background: Generalized anxiety disorder (GAD) is a persistent mental illness that causes significant distress and impairment in functioning. Selective serotonin reuptake inhibitors (SSRIs) are often used in the treatment of GAD, but evidence for fluoxetine in particular is not as well established as for some other pha...

Sehasbir Singh, Haseeb Mohammad · 0 citations
Sep 2026

Low-Dose Clozapine Versus Aripiprazole in Borderline Personality Disorder: A Prospective Naturalistic Study.

BACKGROUND Borderline personality disorder (BLPD) is a complex and debilitating psychiatric condition with high prevalence and clinical and psychosocial burden. Psychotherapy is the recommended first-line treatment but, in real-world clinical practice, most individuals with BLPD are prescribed psychotropic medications,...

M. D'Incalci, C. M. Congedo, G. Agostoni et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.